



## Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

September 1, 2026

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright 28th Annual Global Investment Conference taking place in New York, NY and will present a company overview at 2 p.m. ET on September 15, 2026.

A live webcast of the presentation will be accessible [here](#) and will be available for replay on the "Events and Presentations" section of Seres' website following the event.

### About Seres Therapeutics

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage biotechnology company developing novel live biotherapeutics products, designed to address unmet needs in oncology that can lead to interruption to patients' cancer care and/or mortality, and to treat inflammatory and immune diseases, by modulating host function to protect and improve mucosal epithelial barrier integrity, induce immune homeostasis and tolerance, and prevent the colonization and overgrowth of pathogens in the gastrointestinal (GI) tract. The Company previously led the development and FDA approval of VOWST™, the first orally administered microbiome therapeutic, which was subsequently divested to Nestlé Health Science. SER-155, an investigational cultivated multi-strain biotherapeutic, which has received Breakthrough Therapy and Fast Track designations, is being advanced for the prevention of bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant, and is Phase 2 ready, pending receipt of funding. SER-155 is also being developed to address immune checkpoint inhibitor-related enterocolitis (irEC) to provide an immunosuppressive-free alternative and enable patients to continue their ICI cancer therapy. Having recently reported promising results from an investigator sponsored trial, Seres is evaluating the design of a Phase 2 study in irEC. The Company is advancing IND-enabling studies for SER-603, which is in development for inflammatory bowel disease. Mechanistically, Seres' biotherapeutics target the mucosal epithelial barrier-immune interface and are optimized to modulate host function to increase mucosal epithelium integrity, induce immune homeostasis, and prevent the colonization and overgrowth of harmful bacteria in the GI tract. For more information, please visit [www.serestherapeutics.com](http://www.serestherapeutics.com).

### Investor and Media Contact:

[IR@serestherapeutics.com](mailto:IR@serestherapeutics.com)

Carlo Tanzi, Ph.D.  
Kendall Investor Relations  
[ctanzi@kendallir.com](mailto:ctanzi@kendallir.com)

